Suppr超能文献

急性给予大麻二酚可减少酒精使用障碍患者的酒精渴望及线索诱导的伏隔核激活:双盲随机对照ICONIC试验

Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial.

作者信息

Zimmermann Sina, Teetzmann Anton, Baeßler Joscha, Schreckenberger Lena, Zaiser Judith, Pfisterer Marlen, Stenger Manuel, Bach Patrick

机构信息

Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim/ University of Heidelberg, Heidelberg, Germany.

German Center for Mental Health (DZPG), Mannheim, Germany.

出版信息

Mol Psychiatry. 2025 Jun;30(6):2612-2619. doi: 10.1038/s41380-024-02869-y. Epub 2024 Dec 12.

Abstract

Although alcohol use disorder (AUD) is highly prevalent, only a few medications are approved for its treatment leaving much room for improvement. Cannabidiol (CBD) might be a particularly promising candidate, with preclinical data suggesting that CBD is effective in targeting AUD symptoms and disease processes that drive alcohol use and relapse, due to its anti-craving, stress-reducing, and anti-compulsive effects. Here we report data from the double-blind randomized controlled ICONIC trial that compared the effects of a single dose of 800 mg cannabidiol against placebo (PLC) in N = 28 individuals with AUD. Cue-induced nucleus accumbens (NAc) activation, alcohol craving during a combined stress- and alcohol cue exposure session, as well as craving during an fMRI alcohol cue-reactivity task and CBD plasma levels served as outcomes. Individuals receiving CBD showed lower bilateral cue-induced NAc activation (t = 4.906, p < 0.001, d = 1.15; t = 4.873, p < 0.001, d = 1.13) and reported significantly lower alcohol craving after a combined stress- and alcohol cue exposure session (F = 4.516, p = 0.043, eta = 0.15) and during the fMRI cue-reactivity task (F = 6.665, p = 0.015, eta = 0.23). CBD levels were significantly higher in the CBD group (t = 3.808, p < 0.001, d = 1.47) and showed a significant negative association with alcohol craving during the cue exposure experiment (r = -0.394, p = 0.030) and during fMRI (r = -0.389, p = 0.030), and with left and right NAc activation (r_ = -0.459, p = 0.030; r_ = -0.405, p = 0.030). CBD's capacity to reduce stress- and cue-induced alcohol craving and to normalize NAc activation - a region critical to the pathophysiology of AUD - contribute to understanding the neurobiological basis of its clinical effects and support its potential as a treatment option for AUD. Clinical Trials Registry: DRKS00029993.

摘要

尽管酒精使用障碍(AUD)非常普遍,但仅有少数药物被批准用于其治疗,仍有很大的改进空间。大麻二酚(CBD)可能是一个特别有前景的候选药物,临床前数据表明,由于其抗渴望、减轻压力和抗强迫作用,CBD可有效针对导致酒精使用和复发的AUD症状及疾病过程。在此,我们报告了双盲随机对照ICONIC试验的数据,该试验比较了单剂量800毫克大麻二酚与安慰剂(PLC)对28名AUD患者的影响。线索诱导的伏隔核(NAc)激活、在压力和酒精线索联合暴露期间的酒精渴望、功能磁共振成像(fMRI)酒精线索反应任务期间的渴望以及CBD血浆水平作为研究结果。接受CBD的个体双侧线索诱导的NAc激活较低(t = 4.906,p < 0.001,d = 1.15;t = 4.873,p < 0.001,d = 1.13),并且在压力和酒精线索联合暴露后(F = 4.516,p = 0.043,η = 0.15)以及在fMRI线索反应任务期间(F = 6.665,p = 0.015,η = 0.23)报告的酒精渴望显著降低。CBD组的CBD水平显著更高(t = 3.808,p < 0.001,d = 1.47),并且在线索暴露实验期间(r = -0.394,p = 0.030)以及在fMRI期间(r = -0.389,p = 0.030)与酒精渴望呈显著负相关,与左右NAc激活也呈负相关(r_ = -0.459,p = 0.030;r_ = -0.405,p = 0.030)。CBD降低压力和线索诱导的酒精渴望以及使NAc激活正常化的能力——NAc是AUD病理生理学的关键区域——有助于理解其临床效果的神经生物学基础,并支持其作为AUD治疗选择的潜力。临床试验注册编号:DRKS00029993。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5644/12092268/5f3bd3687364/41380_2024_2869_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验